How State AGs Are Reshaping Federal Abortion Policy

Key Takeaways

• The U.S. Supreme Court will decide by May 14, 2026, whether to reinstate the mifepristone in-person dispensing requirement nationwide, potentially reversing a 2023 FDA change that allowed abortion medication access via telehealth and mail order.
• Louisiana's lawsuit argues that removing the in-person requirement harms the state by interfering with its abortion laws, increasing healthcare costs, and creating public health concerns—claims that both a district court and the Fifth Circuit found could succeed.
• Republican attorneys general have filed multiple cases to establish standing after the Supreme Court dismissed an earlier mifepristone challenge, with Louisiana's case emerging as the most impactful because it directly targets FDA mifepristone REMS telehealth provisions.
• The legal battle extends beyond federal courts, as Republican states pursue criminal and civil cases against out-of-state abortion medication providers while Democratic states use shield laws to block extraditions and investigations.
• The Supreme Court's upcoming decision won't resolve the broader conflict over state abortion medication laws, as the FDA's regulatory review is due later this year and interstate enforcement disputes between states remain ongoing.

---

The U.S. Supreme Court is set to decide by May 14, 2026, whether to reinstate the in-person dispensing requirement for mifepristone nationwide — a ruling that would mark the most significant change to abortion medication access since the Dobbs decision in 2022. The case is the latest development in an increasingly complex battleground in reproductive policy, one that has evolved into a broader conflict involving attorneys general, the courts, federal agencies, and state lawmakers. Republican attorneys general have pursued an aggressive legal strategy in the courts, while state lawmakers enact new legislation to bolster their chances of success.

Legal Background: From FDA v. Alliance for Hippocratic Medicine to State-Led Challenges

Since Dobbs, abortion medication first made it to the U.S. Supreme Court in 2024 with FDA v. Alliance for Hippocratic Medicine, when a group of physicians challenged the FDA’s approval of mifepristone (the first of two medications used in a medication abortion regimen). The Court ultimately rejected the case, determining that the plaintiffs lacked standing since they could not prove harm. However, the Court refrained from ruling on the merits of the case and left the door open to future challenges by parties better positioned to establish standing.

Multiple States File New Lawsuits to Establish Standing

Republican attorneys general have filed several lawsuits to cure the standing problems that sank the original case. Following the dismissal of FDA v. Alliance for Hippocratic Medicine, Missouri, Kansas, and Idaho filed an amended complaint and were allowed to continue the challenge. In 2025, Texas, Florida, and Louisiana also attempted to join the case, arguing that the original three states may no longer be well-positioned to maintain standing, citing Missouri voters' 2024 approval of constitutional abortion protections, a potential 2026 Idaho ballot measure, and Kansas Supreme Court rulings in 2019 and 2024 affirming the right to abortion. However, a district court denied the motions to intervene, leading Texas and Florida to file their own case with similar claims, while Louisiana Attorney General Liz Murrill (R) filed a separate lawsuit. Murrill is also joined in the case by a woman who claims her boyfriend coerced her into taking mifepristone obtained from a California doctor.

Louisiana's Challenge to FDA Telehealth and Mail Order Rules

Louisiana’s lawsuit has emerged as the most significant case because it specifically focuses on a 2023 FDA change to mifepristone’s Risk Evaluation and Mitigation Strategy (REMS) that removed the in-person dispensing requirement for mifepristone and allowed the drug to be prescribed via telehealth and distributed by mail. The state argues that the change harms the state in several direct ways. It contends that it interferes with Louisiana’s sovereign authority to enforce its abortion laws, causes public harm by injuring unborn children as well as women with health complications associated with medication abortions, and creates economic harms by increasing Medicaid and uncompensated care costs related to mifepristone complications.

Fifth Circuit Reinstates In-Person Dispensing Requirement

The litigation has also been intertwined with activity at the federal level. In July 2025, 22 Republican attorneys general wrote a letter to the FDA urging a review of the drug, and in September 2025, the FDA affirmed its commitment to conducting a study of regulations on the drugs to determine whether modifications are necessary. The Trump Administration subsequently filed a request to pause the Louisiana case until the FDA completes its review, contending that judicial action may be unnecessary and disruptive given the review. In response, Florida and Texas agreed to pause their lawsuit, and last month, a federal district court judge placed a stay on Louisiana’s case and ordered the FDA to provide an update in six months. However, Louisiana AG Murrill persisted and asked the Fifth Circuit Court of Appeals to block the 2023 REMS change. Last week, the Fifth Circuit granted this request and reinstated the in-person dispensing requirement for mifepristone nationwide. However, following an emergency appeal, the U.S. Supreme Court issued orders putting the stay on hold until May 14 and restoring access via telehealth and mail order while the Court considers the request.

Notably, both the federal district court judge and the Fifth Circuit found that Louisiana likely has standing and could ultimately prevail on parts of its claims. The Trump Administration has not weighed in since the case made it to the U.S. Supreme Court, but in its previous request to pause the case, the Administration suggested that the plaintiffs lacked standing and should sue abortion medication providers rather than the administration. Republican attorneys general have been pursuing this tactic with several civil and criminal cases in Texas and Louisiana against providers in New York, California, and Delaware who are alleged to have sent abortion medications into the states in violation of state abortion laws.

Interstate Enforcement Conflicts Between Red and Blue States

Those cases have intensified legal conflict with Democratic-led states that have enacted shield laws intended to protect providers against out-of-state investigations and extraditions. Attorney General Murrill specifically highlighted this point in Louisiana's complaint, noting that New York Governor Kathy Hochul (D) has refused to extradite a New York doctor indicted in Louisiana, citing New York's shield law. At the same time, Republican lawmakers have escalated the conflict by enacting laws to further restrict abortion medication and enhance enforcement mechanisms. Louisiana AG Murrill contends that state-level enforcement efforts may be insufficient to stop interstate distribution of abortion medications, reinforcing the argument that federal regulatory changes are necessary.

What Happens Next: Supreme Court Decision and Ongoing Litigation

The U.S. Supreme Court's decision — expected this week — will determine how the Louisiana case proceeds in the near term, but it will not resolve the underlying conflict. The FDA's regulatory review is due later this year, additional state cases against out-of-state providers are working through the courts, and shield-law disputes between Democratic and Republican states remain unsettled. Regardless of the outcome, states will continue to employ overlapping legislative, regulatory, and litigation strategies, and the broader legal and policy fight surrounding abortion medication is far from over.

Track Legal Activity and Other Policy Activity

Federal and state legal activity can have significant policy and regulatory implications for businesses and organizations. If your organization would like to further track federal and state legal activity, please contact us.